Arrivent Biopharma Inc
NASDAQ:AVBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (10.1), the stock would be worth $-45.8 (248% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -6.9 | $31 |
0%
|
| Industry Average | 10.1 | $-45.8 |
-248%
|
| Country Average | 16.7 | $-75.41 |
-343%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
A
|
Arrivent Biopharma Inc
NASDAQ:AVBP
|
1.3B USD | -6.9 | -7.9 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.9B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 45 425.5 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.4B ZAR | 18.1 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68B USD | -45 946.1 | 38 417.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
58.9B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.6B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
37.6B USD | 41.9 | -3 457.1 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 17.8 | 174.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.1B ZAR | 17.4 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Arrivent Biopharma Inc
Glance View
Arrivent Biopharma Inc is a US-based company operating in industry. The company is headquartered in Newtown Square, Pennsylvania and currently employs 40 full-time employees. The company went IPO on 2024-01-26. ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. The company is also focused on development and commercialization of the ARR-002 program.
